The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Arsenical drugs have achieved hallmark success in treating patients with acute promyelocytic leukemia, but expanding their clinical utility to solid tumors has proven difficult with the contradiction between the therapeutic efficacy and the systemic toxicity. Here, leveraging efforts from materials science, biocompatible PEGylated arsenene nanodots (AsNDs@PEG) with high monoelemental arsenic purity...
Arsenical Drugs
In article number 2102054, Aiguo Wu, Tian Xie, Wei Tao, and co‐workers reveal PEGylated arsenene nanodots (AsNDs@PEG) with high monoelemental arsenic purity and negligible systemic toxicity as a new‐concept arsenical drug. This AsNDs@PEG, when applied in a low‐dose combination strategy with β‐elemene, a plant‐derived anticancer drug, achieves synergistic therapeutic outcomes.
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.